Massachusetts Financial Services
NTLA icon

Massachusetts Financial Services’s Intellia Therapeutics NTLA Stock Holding History

Massachusetts Financial Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$561K Sell
33,160
-1,322
-4% -$18.5K ﹤0.01% 944
2026
Q1 		$442K Sell
34,482
-916
-3% -$11.7K ﹤0.01% 900
2025
Q4 		$318K Buy
+35,398
New +$487K ﹤0.01% 895

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Massachusetts Financial Services's NTLA Position: Q2 2026 in Review

Massachusetts Financial Services reduced its Intellia Therapeutics (NTLA) stake by 3.8% in Q2 2026, selling an estimated $18.5K and leaving 33,160 shares worth $561K. The position accounts for ﹤0.01% of the portfolio, ranked #944.

Massachusetts Financial Services first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Massachusetts Financial Services held 33,160 shares of Intellia Therapeutics worth $561K as of Q2 2026.
  • Massachusetts Financial Services sold 1,322 Intellia Therapeutics shares in Q2 2026, an estimated $18.5K.
  • Intellia Therapeutics made up ﹤0.01% of Massachusetts Financial Services's portfolio in Q2 2026, its #944 holding.
  • Massachusetts Financial Services first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Massachusetts Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.